NEW YORK ( TheStreet) -- Today's trading action is nothing more than a healthily pause after a spectacular run high, Jim Cramer told the viewers of his "Mad Money" TV show Friday. "The markets are just catching their breath," said Cramer, as he outlined his game plan for next week's trading. On Monday, Cramer said Enbridge Energy Partners ( EEP) will report and he's still bullish on this 6.4% yielder along with all of the pipeline master limited partnerships. He said to avoid anything dealing with propane, like Suburban Propane ( SPH). For Tuesday, Cramer will be watching ARM Holdings ( ARMH) and Amazon.com ( AMZN). Cramer said he'd be a buyer of KLA-Tencor ( KLAC) if ARM reports good numbers, but he'd take a "wait-and-see" approach to Amazon. Wednesday brings Whirlpool ( WHR), Chipotle Mexican Grill ( CMG), Tractor Supply ( TSCO) and Core Labs ( CLB). Cramer said he'll be listening to see if housing is back with Whirlpool and will be expecting good things from Tractor Supply. He suggested waiting on Chipotle, which hit an all-time high, but would be a buyer of Core Labs when it sells off after it reports. In related retailed news, Cramer said to sell JC Penney ( JCP), which has now gotten way ahead of itself. > >> Bull or Bear? Vote in Our Poll Then on Thursday, Allergan ( AGN), Cummins ( CMI) and Dow Chemical ( DOW) take center stage. Cramer said he would buy Allergan and Dow on any weakness, but would take profits in Cummins, a stock which he owns for his charitable trust,
Dead MoneyAfter reporting disappointing results earlier today, Cramer asked the question, "is the Ford story finished?" He said in his opinion, is would be wrong to give up on Ford ( F), but he had some sharp criticisms for its management. Cramer said that Ford was a classic case of over-promising and under-delivering. He said the company should have pre-announced its earnings shortfall as soon as it knew things were heading south and not leave investors in the dark. Cramer noted that the weakness in Europe was a known factor, and when the flooding in Thailand also occurred it became worthy of a pre-announcement. He said the commodity price pressures that Ford faced were also foreseeable, making the "surprise" disappointment even more unacceptable. Ford is indeed rebuilding a great balance sheet, said Cramer, but when things go materially wrong, the right thing to do is reset the bar early and far lower than you're expecting. Cramer also would have waited to boost the company's dividend, he said, until management had a better handle onthe weakness. Ford's stock, he said, is now dead money: too low to sell but too high to buy. Cramer once again recommended playing the auto sector through the parts makers and not via the big auto companies themselves
Euro Turns Into TailwindFor his final "Breakthrough Medical Stock," Cramer recommended Sanofi Aventis ( SNY), the world's fourth largest drug company and an Action Alerts PLUS holding. Cramer explained that Sanofi lagged the markets last year simply because the company is based in France, causing it to get slammed with the price of the euro. But just as the euro was a headwind last year, he said the the currency risk in the company is now a tailwind going into 2012. But more important than its nationality is the company itself. he said. According to Cramer, investors have been worried for years that 2012 would be a disaster for the company as its three main drugs, including its blockbuster Plavix, lose their patent protection. While investors fretted however, Cramer said Sanofi's management has been taking radical steps to both minimize the damage and prevent similar scenarios from occurring in the future. In 2008, Sanofi's "big three" drugs accounted for 27% of the company's sales, but after rapidly diversifying itself into vaccines, generic drugs, consumer products and animal health products, those drugs now account for just 9% of sales. That's why the company has forecast sales growth of 5% a year through 2015, said Cramer. Sanofi is now one of the largest makers of vaccines, drugs that are immune to economic turmoil and are hard to copy. The company is also a leader in emerging markets, which now account for 33% of sales. Additionally, thanks to its Genzyme acquisition, Sanofi also has exposure to lucrative orphan drugs as well as high-cost savings than it originally forecast. For all these reasons, Cramer said that Sanofi Aventis remains his favorite in the drug group.